France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...

France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.

French pharma major Sanofi delivered a set of first-quarter financial results that seemed to satisfy markets Thursday, as its ...

France's Sanofi (SASY.PA), opens new tab reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria (CSU), a condition that causes painful hives that often don't respond to ...

Sanofi reported net sales growth of 9.7% at constant currency and business earnings per share growth of 15.7%, largely driven by Dupixent and Altuviiio. It reiterated its previous full-year ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...